FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136371725> ?p ?o ?g. }

• W3136371725 endingPage "e000782" @default.
• W3136371725 startingPage "e000782" @default.
• W3136371725 abstract "Background Pirfenidone and nintedanib are the only disease-modifying treatments available for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in clinical practice. Methods This is a single-centre retrospective observational study undertaken at a specialised interstitial lung disease centre in England. Data including progression-free survival (PFS), mortality and drug tolerability were compared between patients with IPF on antifibrotic therapies and an untreated control group who had a forced vital capacity percentage (FVC %) predicted within the licensed antifibrotic treatment range. Results 104 patients received antifibrotic therapies and 64 control patients were identified. PFS at 6 months was significantly greater in the antifibrotic group (75.0%) compared with the control group (56.3%) (p=0.012). PFS was not significant at 12 or 18 months when comparing the antifibrotic group with the control group. The 12-month post-treatment mean decline in FVC % predicted (−4.6±6.2%) was significantly less than the 12-month pretreatment decline (−10.4±11.8%) (p=0.039). The 12-month mortality rate was not significantly different between the antifibrotic group (25.3%) and the control group (35.5%) (p=0.132). Baseline Body Mass Index of≤25, baseline diffusion capacity for carbon monoxide percentage predicted of ≤35 and antifibrotic discontinuation within 3 months were independent predictors of 12-month mortality. Antifibrotic discontinuation was significantly higher by 3 and 6 months for patients on pirfenidone than those on nintedanib (p=0.006 and p=0.044, respectively). Discontinuation at 12 months was not significantly different (p=0.381). Conclusions This real-world study revealed that antifibrotics are having promising effects on PFS, lung function and mortality. These findings may favour commencement of nintedanib as first-line antifibrotic therapy, given the lower rates of early treatment discontinuation, although further studies are required to investigate this." @default.
• W3136371725 created "2021-03-29" @default.
• W3136371725 creator A5031679555 @default.
• W3136371725 creator A5043836434 @default.
• W3136371725 creator A5055576790 @default.
• W3136371725 creator A5072021354 @default.
• W3136371725 creator A5084026477 @default.
• W3136371725 creator A5084886322 @default.
• W3136371725 creator A5087933656 @default.
• W3136371725 date "2021-03-01" @default.
• W3136371725 modified "2023-10-06" @default.
• W3136371725 title "Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis" @default.
• W3136371725 cites W1943724554 @default.
• W3136371725 cites W1964124382 @default.
• W3136371725 cites W2045756883 @default.
• W3136371725 cites W2057292199 @default.
• W3136371725 cites W2058408736 @default.
• W3136371725 cites W2080677332 @default.
• W3136371725 cites W2098305693 @default.
• W3136371725 cites W2136410669 @default.
• W3136371725 cites W2138871107 @default.
• W3136371725 cites W2168666423 @default.
• W3136371725 cites W2208096782 @default.
• W3136371725 cites W2272059546 @default.
• W3136371725 cites W2510319197 @default.
• W3136371725 cites W2550523848 @default.
• W3136371725 cites W2554641751 @default.
• W3136371725 cites W2569766637 @default.
• W3136371725 cites W2597638604 @default.
• W3136371725 cites W2604367936 @default.
• W3136371725 cites W2766726468 @default.
• W3136371725 cites W2788452276 @default.
• W3136371725 cites W2797176335 @default.
• W3136371725 cites W2889197569 @default.
• W3136371725 cites W2903949926 @default.
• W3136371725 cites W2945669136 @default.
• W3136371725 cites W2967440899 @default.
• W3136371725 cites W2978206657 @default.
• W3136371725 cites W3003269956 @default.
• W3136371725 cites W3004184893 @default.
• W3136371725 cites W3010529169 @default.
• W3136371725 doi "https://doi.org/10.1136/bmjresp-2020-000782" @default.
• W3136371725 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8006845" @default.
• W3136371725 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33771813" @default.
• W3136371725 hasPublicationYear "2021" @default.
• W3136371725 type Work @default.
• W3136371725 sameAs 3136371725 @default.
• W3136371725 citedByCount "19" @default.
• W3136371725 countsByYear W31363717252021 @default.
• W3136371725 countsByYear W31363717252022 @default.
• W3136371725 countsByYear W31363717252023 @default.
• W3136371725 crossrefType "journal-article" @default.
• W3136371725 hasAuthorship W3136371725A5031679555 @default.
• W3136371725 hasAuthorship W3136371725A5043836434 @default.
• W3136371725 hasAuthorship W3136371725A5055576790 @default.
• W3136371725 hasAuthorship W3136371725A5072021354 @default.
• W3136371725 hasAuthorship W3136371725A5084026477 @default.
• W3136371725 hasAuthorship W3136371725A5084886322 @default.
• W3136371725 hasAuthorship W3136371725A5087933656 @default.
• W3136371725 hasBestOaLocation W31363717251 @default.
• W3136371725 hasConcept C126322002 @default.
• W3136371725 hasConcept C141071460 @default.
• W3136371725 hasConcept C165637977 @default.
• W3136371725 hasConcept C167135981 @default.
• W3136371725 hasConcept C197934379 @default.
• W3136371725 hasConcept C2777714996 @default.
• W3136371725 hasConcept C2778341716 @default.
• W3136371725 hasConcept C2778375690 @default.
• W3136371725 hasConcept C2778715236 @default.
• W3136371725 hasConcept C2779832356 @default.
• W3136371725 hasConcept C2780171596 @default.
• W3136371725 hasConcept C3018587741 @default.
• W3136371725 hasConcept C55520419 @default.
• W3136371725 hasConcept C71924100 @default.
• W3136371725 hasConcept C90924648 @default.
• W3136371725 hasConceptScore W3136371725C126322002 @default.
• W3136371725 hasConceptScore W3136371725C141071460 @default.
• W3136371725 hasConceptScore W3136371725C165637977 @default.
• W3136371725 hasConceptScore W3136371725C167135981 @default.
• W3136371725 hasConceptScore W3136371725C197934379 @default.
• W3136371725 hasConceptScore W3136371725C2777714996 @default.
• W3136371725 hasConceptScore W3136371725C2778341716 @default.
• W3136371725 hasConceptScore W3136371725C2778375690 @default.
• W3136371725 hasConceptScore W3136371725C2778715236 @default.
• W3136371725 hasConceptScore W3136371725C2779832356 @default.
• W3136371725 hasConceptScore W3136371725C2780171596 @default.
• W3136371725 hasConceptScore W3136371725C3018587741 @default.
• W3136371725 hasConceptScore W3136371725C55520419 @default.
• W3136371725 hasConceptScore W3136371725C71924100 @default.
• W3136371725 hasConceptScore W3136371725C90924648 @default.
• W3136371725 hasFunder F4320334626 @default.
• W3136371725 hasIssue "1" @default.
• W3136371725 hasLocation W31363717251 @default.
• W3136371725 hasLocation W31363717252 @default.
• W3136371725 hasLocation W31363717253 @default.
• W3136371725 hasLocation W31363717254 @default.
• W3136371725 hasOpenAccess W3136371725 @default.
• W3136371725 hasPrimaryLocation W31363717251 @default.

• next